Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of RePlas Freeze Dried Plasma in Healthy Volunteers
NCT02930226Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RePlas in hemorrhage and psychological trauma (6 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests at Day 29. Started Feb 2017; status: completed.
02
Drugs
RePlas
03
Conditions
hemorrhagepsychological trauma
Beyond the preview
Go deeper on NCT02930226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930226.